INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in GSK plc of Class Action Lawsuit and Upcoming Deadlines - GSK
Portfolio Pulse from
Pomerantz LLP has filed a class action lawsuit against GSK regarding potential securities fraud related to the Zantac drug recall. In 2019, GSK suspended Zantac distribution after studies revealed the drug could create a carcinogenic compound. Deutsche Bank analysts suggested potential liability between $5-10 billion, which GSK later confirmed. The stock experienced price drops following these revelations.
March 27, 2025 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Class action lawsuit highlights potential securities fraud and substantial liability from Zantac drug recall, with estimated damages between $1-10 billion.
The lawsuit and potential massive liability directly impact GSK's financial standing, likely causing investor uncertainty and potential stock price decline.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100